Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO 09 December 2020
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical... Read more
Press Release LINK Medical has today announced the acquisition of IRW Consulting AB (IRW), a Nordic CRO... Read more
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical... Read more
Y-mAbs Therapeutics, Inc. today announced a clinical update on omburtamab for the treatment of diffuse... Read more
As mentioned in a previous Newsletter, DANSK BIOTEK has joined the newly established Genstartsteam (Restart... Read more
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer... Read more
Y-mAbs Therapeutics, Inc. today announced that it will report its financial results for the third quarter... Read more
As a member of DANSK BIOTEK you are invited to participate in this survey mapping patient stratification... Read more